Fw: URGENT!! CRITICAL!!! COMMENT THE FDA TO OVERTHROW THE 2009 DECISION????????????

[Guest guest]

From: lindabrocato@... <lindabrocato@...>

Subject: URGENT!! CRITICAL!!! COMMENT THE FDA TO OVERTHROW THE 2009

DECISION????????????

 Thursday, July 29, 2010, 9:12 AM

CDC #1

 

7-29-2010

 

HI FOLKS-

 

URGENT- NEED YOUR HELP AGAIN! PLEASE TAKE A MOMENT AND READ AND WRITE YOUR

COMMENTS TO THE FDA. THIS IS CRITICAL AND COULD CHANGE THE 2009 FDA DEBACLE OF

JULY 28, 2009 STATING THAT " MERCURY " AMALGAM FILLINGS ARE " SAFE " FOR EVERYONE!!!

 

The docket number is FDA–2010–N–0268. The docket will be open for public

comment on June 11, 2010. The docket will close on December 3, 2010.

 

Interested persons are encouraged to use the docket to submit either electronic

or written comments regarding this meeting. Submit electronic comments to

http://www.regulations.gov.

Submit written comments to the

Division of Dockets Management,

Food and Drug Administration,

5630 Fishers Lane, rm. 1061,

Rockville, MD 20852.

 

It is only necessary to send one set of comments. It is no longer necessary to

send two copies of mailed comments. Identify comments with the docket number

found in brackets in the heading of this document. Received comments may be seen

in the Division of Dockets Management between 9 a.m. and 4 p.m.,Monday through

Friday.

 

Agenda: On December 14 and 15, 2010, the committee will discuss and make

recommendations on scientific issues raised in petitions received by FDA

concerning the final rule on the classification of dental amalgam, which

published in the Federal Register on August 4, 2009 (74 FR 38686). These

petitions (docket numbers FDA–2008–N–0163 and FDA–2009–P–0357) can

be viewed at

http://www.regulations.gov/search/Regs/home.html#documentDetail?R=09000064809fbe\

3f; http://www.regulations.gov/search/Regs/home.html#documentDetail?

R=0900006480a1d1bc; http://www.regulations.gov/search/Regs/

home.html#documentDetail?

R=0900006480a24048; and http://

www.regulations.gov/search/Regs/

home.html#documentDetail?

R=0900006480a80ae5.

Issues raised in the petitions include the adequacy of the risk assessment

performed by FDA in classifying dental amalgam in light of a new report on risk

assessments issued by the National Academy of Sciences, entitled ‘‘Science

and Decisions:Advancing Risk Assessment,’’ NAP, 2009.

FDA intends to make background material available to the public no later

than 2 business days before the meeting. If FDA is unable to post the background

material on its Web site prior to the meeting, the background material will be

made publicly available at the location of the advisory committee

meeting, and the background material will be posted on FDA’s Web site after

the meeting. Background material is available at http://www.fda.gov/

AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory

committee link.

 

Procedure: Interested persons may present data, information, or views, orally or

in writing, on issues pending before the committee. Written submissions may be

made to the contact person on or before December 6, 2010.

 

Oral presentations from the public will be scheduled at 1 p.m. on December 14,

2010 and at 8 a.m. on December 15, 2010. Those desiring to make formal oral

presentations should notify the contact person and submit a brief statement of

the general nature of the evidence or arguments they wish to

present, the names and addresses of proposed participants, and an indication of

the approximate time requested to make their presentation on or before November

29, 2010. Time allotted for each presentation may be limited. If the number of

registrants requesting to speak is greater than can be reasonably accommodated

during the scheduled open public hearing session, FDA may conduct a lottery to

determine the speakers for the scheduled open public hearing session. The

contact person will notify interested persons regarding their request to speak

by December 1, 2010. Persons attending FDA’s advisory committee meetings are

advised that the agency is not responsible for providing access to electrical

outlets.

 

FDA welcomes the attendance of the public at its advisory committee meetings and

will make every effort to accommodate persons with physical disabilities or

special needs. If you require special accommodations due to a disability, please

contact AnnMarie , Conference Management

Staff, 301–796–5966, at least 7 days in advance of the meeting.

 

FDA is committed to the orderly conduct of its advisory committee meetings.

Please visit our Web site at http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public

conduct during advisory committee meetings. Notice of this meeting is given

under the Federal Advisory Committee Act (5U.S.C. app. 2).Dated: June 8,

2010.Jill Hartzler Warner, Acting Associate Commissioner for Special Medical

Programs.

[FR Doc. 2010–14084 Filed 6–10–10; 8:45 am]

 

THANKS,

 

LINDA BROCATO

#yiv523586266 .yiv523586266AOLWebSuite .yiv523586266AOLPicturesFullSizeLink

{height:1px;width:1px;overflow:hidden;}#yiv523586266 .yiv523586266AOLWebSuite a

{color:blue;text-decoration:underline;cursor:pointer;}#yiv523586266

..yiv523586266AOLWebSuite a.yiv523586266hsSig {cursor:default;}

[Guest guest]

I think the FDA stands for " For Drugging Americans. "

I will definitely send in comment.